Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth

Khuloud T Al-Jamal, Wafa' T Al-Jamal, Simon Akerman, Jennifer E Podesta, Açelya Yilmazer, John A Turton, Alberto Bianco, Neil Vargesson, Chryso Kanthou, Alexander T Florence, Gillian M Tozer, Kostas Kostarelos

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

This study describes the previously unreported intrinsic capacity of poly-L-lysine (PLL) sixth generation (G(6)) dendrimer molecules to exhibit systemic antiangiogenic activity that could lead to solid tumor growth arrest. The PLL-dendrimer-inhibited tubule formation of SVEC4-10 murine endothelial cells and neovascularization in the chick embryo chick chorioallantoic membrane (CAM) assay. Intravenous administration of the PLL-dendrimer molecules into C57BL/6 mice inhibited vascularisation in Matrigel plugs implanted subcutaneously. Antiangiogenic activity was further evidenced using intravital microscopy of tumors grown within dorsal skinfold window chambers. Reduced vascularization of P22 rat sarcoma implanted in the dorsal window chamber of SCID mice was observed following tail vein administration (i.v.) of the PLL dendrimers. Also, the in vivo toxicological profile of the PLL-dendrimer molecules was shown to be safe at the dose regime studied. The antiangiogenic activity of the PLL dendrimer was further shown to be associated with significant suppression of B16F10 solid tumor volume and delayed tumor growth. Enhanced apoptosis/necrosis within tumors of PLL-dendrimer-treated animals only and reduction in the number of CD31 positive cells were observed in comparison to protamine treatment. This study suggests that PLL-dendrimer molecules can exhibit a systemic antiangiogenic activity that may be used for therapy of solid tumors, and in combination with their capacity to carry other therapeutic or diagnostic agents may potentially offer capabilities for the design of theranostic systems.
Original languageEnglish
Pages (from-to)3966-3971
Number of pages6
JournalPNAS
Volume107
Issue number9
Early online date11 Feb 2010
DOIs
Publication statusPublished - 2 Mar 2010

Fingerprint

Dendrimers
Lysine
Growth
Neoplasms
Chorioallantoic Membrane
Protamines
SCID Mice
Chick Embryo
Tumor Burden
Inbred C57BL Mouse
Sarcoma
Intravenous Administration
Toxicology
Tail
Veins
Necrosis
Therapeutics
Endothelial Cells
Apoptosis

Keywords

  • angiogenesis
  • cancer
  • nanoparticle
  • endothelial cells
  • angiogenesis inhibitors
  • drug delivery
  • long term
  • in vitro
  • mice
  • oligonucleotide
  • chemotherapy

Cite this

Al-Jamal, K. T., Al-Jamal, W. T., Akerman, S., Podesta, J. E., Yilmazer, A., Turton, J. A., ... Kostarelos, K. (2010). Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. PNAS, 107(9), 3966-3971 . https://doi.org/10.1073/pnas.0908401107

Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. / Al-Jamal, Khuloud T; Al-Jamal, Wafa' T; Akerman, Simon; Podesta, Jennifer E; Yilmazer, Açelya; Turton, John A; Bianco, Alberto; Vargesson, Neil; Kanthou, Chryso; Florence, Alexander T; Tozer, Gillian M; Kostarelos, Kostas.

In: PNAS, Vol. 107, No. 9, 02.03.2010, p. 3966-3971 .

Research output: Contribution to journalArticle

Al-Jamal, KT, Al-Jamal, WT, Akerman, S, Podesta, JE, Yilmazer, A, Turton, JA, Bianco, A, Vargesson, N, Kanthou, C, Florence, AT, Tozer, GM & Kostarelos, K 2010, 'Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth', PNAS, vol. 107, no. 9, pp. 3966-3971 . https://doi.org/10.1073/pnas.0908401107
Al-Jamal KT, Al-Jamal WT, Akerman S, Podesta JE, Yilmazer A, Turton JA et al. Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. PNAS. 2010 Mar 2;107(9):3966-3971 . https://doi.org/10.1073/pnas.0908401107
Al-Jamal, Khuloud T ; Al-Jamal, Wafa' T ; Akerman, Simon ; Podesta, Jennifer E ; Yilmazer, Açelya ; Turton, John A ; Bianco, Alberto ; Vargesson, Neil ; Kanthou, Chryso ; Florence, Alexander T ; Tozer, Gillian M ; Kostarelos, Kostas. / Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. In: PNAS. 2010 ; Vol. 107, No. 9. pp. 3966-3971 .
@article{c29c4ece4dc24c7c9013c9dcbb3b38ef,
title = "Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth",
abstract = "This study describes the previously unreported intrinsic capacity of poly-L-lysine (PLL) sixth generation (G(6)) dendrimer molecules to exhibit systemic antiangiogenic activity that could lead to solid tumor growth arrest. The PLL-dendrimer-inhibited tubule formation of SVEC4-10 murine endothelial cells and neovascularization in the chick embryo chick chorioallantoic membrane (CAM) assay. Intravenous administration of the PLL-dendrimer molecules into C57BL/6 mice inhibited vascularisation in Matrigel plugs implanted subcutaneously. Antiangiogenic activity was further evidenced using intravital microscopy of tumors grown within dorsal skinfold window chambers. Reduced vascularization of P22 rat sarcoma implanted in the dorsal window chamber of SCID mice was observed following tail vein administration (i.v.) of the PLL dendrimers. Also, the in vivo toxicological profile of the PLL-dendrimer molecules was shown to be safe at the dose regime studied. The antiangiogenic activity of the PLL dendrimer was further shown to be associated with significant suppression of B16F10 solid tumor volume and delayed tumor growth. Enhanced apoptosis/necrosis within tumors of PLL-dendrimer-treated animals only and reduction in the number of CD31 positive cells were observed in comparison to protamine treatment. This study suggests that PLL-dendrimer molecules can exhibit a systemic antiangiogenic activity that may be used for therapy of solid tumors, and in combination with their capacity to carry other therapeutic or diagnostic agents may potentially offer capabilities for the design of theranostic systems.",
keywords = "angiogenesis, cancer, nanoparticle, endothelial cells, angiogenesis inhibitors, drug delivery, long term, in vitro, mice, oligonucleotide, chemotherapy",
author = "Al-Jamal, {Khuloud T} and Al-Jamal, {Wafa' T} and Simon Akerman and Podesta, {Jennifer E} and A{\cc}elya Yilmazer and Turton, {John A} and Alberto Bianco and Neil Vargesson and Chryso Kanthou and Florence, {Alexander T} and Tozer, {Gillian M} and Kostas Kostarelos",
year = "2010",
month = "3",
day = "2",
doi = "10.1073/pnas.0908401107",
language = "English",
volume = "107",
pages = "3966--3971",
journal = "PNAS",
issn = "0027-8424",
publisher = "NATL ACAD SCIENCES",
number = "9",

}

TY - JOUR

T1 - Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth

AU - Al-Jamal, Khuloud T

AU - Al-Jamal, Wafa' T

AU - Akerman, Simon

AU - Podesta, Jennifer E

AU - Yilmazer, Açelya

AU - Turton, John A

AU - Bianco, Alberto

AU - Vargesson, Neil

AU - Kanthou, Chryso

AU - Florence, Alexander T

AU - Tozer, Gillian M

AU - Kostarelos, Kostas

PY - 2010/3/2

Y1 - 2010/3/2

N2 - This study describes the previously unreported intrinsic capacity of poly-L-lysine (PLL) sixth generation (G(6)) dendrimer molecules to exhibit systemic antiangiogenic activity that could lead to solid tumor growth arrest. The PLL-dendrimer-inhibited tubule formation of SVEC4-10 murine endothelial cells and neovascularization in the chick embryo chick chorioallantoic membrane (CAM) assay. Intravenous administration of the PLL-dendrimer molecules into C57BL/6 mice inhibited vascularisation in Matrigel plugs implanted subcutaneously. Antiangiogenic activity was further evidenced using intravital microscopy of tumors grown within dorsal skinfold window chambers. Reduced vascularization of P22 rat sarcoma implanted in the dorsal window chamber of SCID mice was observed following tail vein administration (i.v.) of the PLL dendrimers. Also, the in vivo toxicological profile of the PLL-dendrimer molecules was shown to be safe at the dose regime studied. The antiangiogenic activity of the PLL dendrimer was further shown to be associated with significant suppression of B16F10 solid tumor volume and delayed tumor growth. Enhanced apoptosis/necrosis within tumors of PLL-dendrimer-treated animals only and reduction in the number of CD31 positive cells were observed in comparison to protamine treatment. This study suggests that PLL-dendrimer molecules can exhibit a systemic antiangiogenic activity that may be used for therapy of solid tumors, and in combination with their capacity to carry other therapeutic or diagnostic agents may potentially offer capabilities for the design of theranostic systems.

AB - This study describes the previously unreported intrinsic capacity of poly-L-lysine (PLL) sixth generation (G(6)) dendrimer molecules to exhibit systemic antiangiogenic activity that could lead to solid tumor growth arrest. The PLL-dendrimer-inhibited tubule formation of SVEC4-10 murine endothelial cells and neovascularization in the chick embryo chick chorioallantoic membrane (CAM) assay. Intravenous administration of the PLL-dendrimer molecules into C57BL/6 mice inhibited vascularisation in Matrigel plugs implanted subcutaneously. Antiangiogenic activity was further evidenced using intravital microscopy of tumors grown within dorsal skinfold window chambers. Reduced vascularization of P22 rat sarcoma implanted in the dorsal window chamber of SCID mice was observed following tail vein administration (i.v.) of the PLL dendrimers. Also, the in vivo toxicological profile of the PLL-dendrimer molecules was shown to be safe at the dose regime studied. The antiangiogenic activity of the PLL dendrimer was further shown to be associated with significant suppression of B16F10 solid tumor volume and delayed tumor growth. Enhanced apoptosis/necrosis within tumors of PLL-dendrimer-treated animals only and reduction in the number of CD31 positive cells were observed in comparison to protamine treatment. This study suggests that PLL-dendrimer molecules can exhibit a systemic antiangiogenic activity that may be used for therapy of solid tumors, and in combination with their capacity to carry other therapeutic or diagnostic agents may potentially offer capabilities for the design of theranostic systems.

KW - angiogenesis

KW - cancer

KW - nanoparticle

KW - endothelial cells

KW - angiogenesis inhibitors

KW - drug delivery

KW - long term

KW - in vitro

KW - mice

KW - oligonucleotide

KW - chemotherapy

U2 - 10.1073/pnas.0908401107

DO - 10.1073/pnas.0908401107

M3 - Article

C2 - 20150514

VL - 107

SP - 3966

EP - 3971

JO - PNAS

JF - PNAS

SN - 0027-8424

IS - 9

ER -